A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

NCT07311694 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: HRS-4357 injection
DRUG: Enzalutamide；Abiraterone

Sponsor

Jiangsu HengRui Medicine Co., Ltd.